News | January 12, 2022
Covaxin booster neutralises Omicron and Delta variants: Study
The study will be published on the pre-print server, medRXiv, shortly
The study will be published on the pre-print server, medRXiv, shortly
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Cobas infinity edge is designed as an open platform, allowing healthcare professionals to easily access and adopt third-party innovators’ new digital tools and medically-relevant applications via the Roche digital marketplace
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Subscribe To Our Newsletter & Stay Updated
